AChE inhibitors are designed to enhance acetylcholine levels in the brain, thereby improving cholinergic neurotransmission and alleviating cognitive deficits associated with Alzheimer’s disease [16]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.